High intratumoral Galectin-1 expression predicts adverse outcome in ALK- ALCL and CD30+ PTCL-NOS

JOHANNE HOLST; MAJA LUDVIGSEN; STEPHEN JACQUES HAMILTON-DUTOIT; KNUD BENDIX; TRINE LINDHARDT PLESNER; PETER NØRGAARD; MICHAEL B. MØLLER; TORBEN STEINICHE; GABRIEL RABINOVICH; FRANCESCO DAMORE; MARTIN BJERREGÅRD PEDERSEN

HEMATOLOGICAL ONCOLOGY

JOHN WILEY & SONS LTD

Lugar: LOndres; Año: 2020

0278-0232

Galectin-1 (Gal-1) has been associated with adverse prognosis in several cancers including lymphoma entities with CD30 expression. However, Gal-1 expression has not been systematically assessed in peripheral T-cell lymphomas (PTCL).Specimens from 169 nodal PTCL were assessed for intratumoral Gal-1 expression byimmunohistochemistry. Overall survival (OS) in groups exhibiting high and low Gal-1 expression was compared in the cohort and in a subset analysis of CD30-positive PTCL only. Gal-1 expression was also correlated with biomarkers of the tumor microenvironment. No significant difference in OS based on Gal-1 expression was observed in the entire PTCL cohort. However, in the CD30-positive cohort, patients with high Gal-1 levels had significantly poorer outcome (5 years OS 10%, 95% confidence interval (CI): 1-36) than their low Gal-1 counterparts (5 years OS 48%, 95%CI: 30-64, P=0.021). In univariateanalyses age≤60, non-elevated LDH, and performance score